Key indicators of phase transition for clinical trials through machine learning.

Clicks: 347
ID: 79765
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 7 articles by views in Drug discovery today

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A significant number of drugs fail during the clinical testing stage. To understand the attrition of drugs through the regulatory process, here we review and advance machine-learning (ML) and natural language-processing algorithms to investigate the importance of factors in clinical trials that are linked with failure in Phases II and III. We find that clinical trial phase transitions can be predicted with an average accuracy of 80%. Identifying these trials provides information to sponsors facing difficult decisions about whether these higher risk trials should be modified or halted. We also find common protocol characteristics across therapeutic areas that are linked to phase success, including the number of endpoints and the complexity of the eligibility criteria.
Reference Key
feijoo2020keydrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feijoo, Felipe;Palopoli, Michele;Bernstein, Jen;Siddiqui, Sauleh;Albright, Tenley E;
Journal Drug discovery today
Year 2020
DOI
S1359-6446(20)30005-2
URL
Keywords
bibliometric analysis prostatectomy citation urological surgery

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.